Xilio Therapeutics, Inc. Revenue 2024–2025
Xilio Therapeutics, Inc. annual/quarterly revenue history and growth rate from 2024 to 2026. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sale of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Xilio Therapeutics, Inc. revenue for the quarter ending March 31, 2026 was 12.6 M, a 331.67% increase year-over-year.
- Xilio Therapeutics, Inc. revenue for the twelve months ending March 31, 2026 was 42.7 M.
- Xilio Therapeutics, Inc. annual revenue for 2025 was 43.8 M, a 589.88% increase from 2024.
- Xilio Therapeutics, Inc. annual revenue for 2024 was 6.3 M.
Xilio Therapeutics, Inc. (XLO) — Frequently Asked Questions
Xilio Therapeutics, Inc. (XLO) is a publicly traded US company. It has a market capitalization of $36M. In fiscal 2025 it reported revenue of $44M and net income of -$35M. Explore XLO's stock price, financial statements, earnings history, margins and key ratios below.
What is Xilio Therapeutics, Inc.'s market cap?
Xilio Therapeutics, Inc. (XLO) has a market capitalization of $36M.
What is the XLO stock price?
XLO trades at $7.90.
How much revenue does Xilio Therapeutics, Inc. make?
Xilio Therapeutics, Inc. reported revenue of $44M in fiscal 2025.
Is XLO profitable?
In fiscal 2025, Xilio Therapeutics, Inc. reported net income of -$35M.